Overview of the WU-PE-CGS
The Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) fills critical gaps in knowledge, methodology, and characterization of understudied cancer populations, leading to optimal approaches to participant engagement, outreach, and communication in genomic characterization studies.
Our focus is on rare and/or understudied cancer populations with significant disparities including:
- Colorectal cancer in Black Americans under age 50
- Multiple myeloma in Black Americans
The WU-PE-CGS builds on a long and outstanding record of leadership in both cancer disparities and genomic research across the cancer continuum. We are particularly innovative and allow for a significant return on the scientific investment in several ways.
- First, our Center has distinctive features that include a combined focus on cancer disparities, the application of strategies to increase participant engagement in research, success in biospecimen acquisition, and exceptional genomic sequencing expertise.
- Second, we have assembled a diverse, world class team with strong linkages to multiple rare and understudied cancers.
- Third, we engage investigators from different disciplines and invest in the development of early career scholars.
- Fourth, we strategically and creatively disseminate products in ways that benefit researchers, practitioners, and community members.
- Fifth, we partner with exceptional patient-centered and wide-reaching advocacy groups to engage patients, optimize recruitment, and seamlessly return results. Input from these groups, patients, and their families is a key strength that leverages our track record of stakeholder engaged research.
- And finally, we have developed a focused strategy for collective integration of our units.
These synergies allow our Center to become a national resource for optimal approaches to participant engagement, outreach, and communication in genomic characterization studies as technologies advance that accelerate progress for the scientific community, patients and their communities.